ARTICLES

Differential effects of epinephrine on glucose production and disposal in man

Normal subjects were infused 1) with epinephrine (50 ng/(kg.min)) for 180 min followed by epinephrine plus glucagon (3 ng/(kg.min)) for 60 min after which the epinephrine infusion rate was increased (125 ng/(kg.min)) or 2) with epinephrine plus somatostatin (500 microgram/h) for 180 min. Epinephrine increased glucose production and plasma glucagon transiently but caused persistent suppression of glucose clearance and sustained hyperglycemia (despite increased plasma insulin and gluconeogenic substrates); glucose production increased again on addition of glucagon and on increasing the epinephrine infusion rate. During epinephrine plus somatostatin, glucose production still increased transiently, but further suppression of glucose clearance caused more marked hyperglycemia. In conclusion, 1) in man hyperepinephrinemia within the physiological range caused sustained suppression of glucose clearance but only a transient increase in glucose production; 2) this transient hepatic response a) was not due to glycogen or substrate depletion, b) occurred without changes in plasma glucagon or insulin, c) was specific for epinephrine but permitted subsequent responses to changes in plasma epinephrine; 3) epinephrine can serve as a physiological regulator of glucose homeostasis in man both by increasing glucose production and by decreasing glucose clearance.

This article has been cited by other articles:

				C. Everett-Grueter, D. S. Edgerton, E. P. Donahue, S. Vaughan, C. A. Chu, D. K. Sindelar, and A. D. Cherrington The effect of an acute elevation of NEFA concentrations on glucagon-stimulated hepatic glucose output Am J Physiol Endocrinol Metab, September 1, 2006; 291(3): E449 - E459. [Abstract] [Full Text] [PDF]

				D. A. Guy, D. Sandoval, M. A. Richardson, D. Tate, P. J. Flakoll, and S. N. Davis Differing physiological effects of epinephrine in type 1 diabetes and nondiabetic humans Am J Physiol Endocrinol Metab, January 1, 2005; 288(1): E178 - E186. [Abstract] [Full Text] [PDF]

				S. M. Gustavson, C. A. Chu, M. Nishizawa, B. Farmer, D. Neal, Y. Yang, E. P. Donahue, P. Flakoll, and A. D. Cherrington Interaction of glucagon and epinephrine in the control of hepatic glucose production in the conscious dog Am J Physiol Endocrinol Metab, April 1, 2003; 284(4): E695 - E707. [Abstract] [Full Text] [PDF]

				C. A. Chu, D. K. Sindelar, K. Igawa, S. Sherck, D. W. Neal, M. Emshwiller, and A. D. Cherrington The direct effects of catecholamines on hepatic glucose production occur via alpha 1- and beta 2-receptors in the dog Am J Physiol Endocrinol Metab, August 1, 2000; 279(2): E463 - E473. [Abstract] [Full Text] [PDF]

				S. H. Kreisman, N. A. Mew, M. Arsenault, S. J. Nessim, J. B. Halter, M. Vranic, and E. B. Marliss Epinephrine infusion during moderate intensity exercise increases glucose production and uptake Am J Physiol Endocrinol Metab, May 1, 2000; 278(5): E949 - E957. [Abstract] [Full Text] [PDF]

				M. C. Lekas, S. J. Fisher, B. El-Bahrani, M. van Delangeryt, M. Vranic, and Z. Q. Shi Glucose uptake during centrally induced stress is insulin independent and enhanced by adrenergic blockade J Appl Physiol, August 1, 1999; 87(2): 722 - 731. [Abstract] [Full Text] [PDF]

				E. Cersosimo, I. N. Zaitseva, and M. Ajmal Effects of beta -adrenergic blockade on hepatic and renal glucose production during hypoglycemia in conscious dogs Am J Physiol Endocrinol Metab, November 1, 1998; 275(5): E792 - E797. [Abstract] [Full Text] [PDF]

				M. Ming, J. Wu, S. Lachance, A. Delalandre, S. Carriere, and J. S. D. Chan ß-Adrenergic Receptors and Angiotensinogen Gene Expression in Mouse Hepatoma Cells In Vitro Hypertension, January 1, 1995; 25(1): 105 - 109. [Abstract] [Full Text]